Table 4.
Results of the probabilistic analysis
| Variables | GClb | RClb | Difference |
|---|---|---|---|
| Total life years (95% CI) | 5.828 (5.209–6,544) | 5.106 (4.469–5.799) | 0.722 (0.555–0.913) |
| In PFS | 2.835 (2.562–3.111) | 1.716 (1.574–1,858) | 1.119 (0.988–1.253) |
| In PD | 2.993 (2.393–3.712) | 3.390 (2.763–4.090) | −0.397 (−0.233 to −0.569) |
| QALYs (95% CI) | 4.036 (3.625–4.480) | 3.359 (2.975–3.774) | 0.677 (0.558–0.808) |
| In PFS | 2.254 (2.027–2.503) | 1.341 (1.222–1.473) | 0.913 (0.803–1.033) |
| In PD | 1.782 (1.413–2.198) | 2.018 (1.641–2.412) | −0.236 (−0.140 to −0.334) |
| Cost (95% CI) | €35,215 (€34,379–36,177) | €18,470 (€17,768–19,258) | €16,745 (€15,829–17,663) |
| In PFS | €32,800 (€32,286–33,392) | €16,084 (€15,743–16,461) | €16,716 (€16,111–17,370) |
| In PD | €2,415 (€1,796–3,208) | €2,386 (€1,784–3,080) | €29 (€–648 to 747) |
| Cost per LYG (GClb vs RClb) (95% CI) | €23,192 (€19,346 to 28,521) | – | – |
| Cost per QALY gained (GClb vs RClb) (95% CI) | €24,734 (€21,860 to 28,367) | – | – |
Abbreviations: CI, confidence interval; GClb, obinutuzumab + chlorambucil; LYG, life years gained; PD, progression disease; PFS, progression-free survival; QALY, quality-adjusted life year; RClb, rituximab + chlorambucil.